Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREFER-HMA: Preference Study of Oral Decitabine/Cedazuridine vs SC Azacitidine
NCT05883956Phase 3Active, not recruiting
- Sponsor
- Otsuka Holdings
- Start
- Dec 2023
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of inqovi in myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML) (2 arms), sponsored by Otsuka Holdings. Primary endpoint: Proportion of patients reporting preference for oral decitabine/cedazuridine vs subcutaneous azacitidine on pTPMQ. Started Dec 2023; status: active, not recruiting.
02
Drugs
inqovi
03
Conditions
myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05883956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05883956.